Excluding Trials News Today

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting Permanent Abstract Number: 1636 Title: Optimized antagonist anti-PD-1/IL-7 mutein bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity. Morello A., Seité M., Durand J, Thépenier V., Teppaz G., Pengam S., Wilhelm E., Desselle A., Girault I., Mary C., Poirier N. Session Type: E-Poste...

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021 News provided by Share this article SAN DIEGO, March 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced the publication of two abstracts that wi...

Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR) Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer Preclinical characterization data will be presented for oral SERD, BCL2 inhibitor, next-generation KRAS-G12C, and RET inhibitors News provided by Share this article Share this article INDIANAPOLIS, Ma...